Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002680 | 0.88 | USP30 (0.40) | ACKR3ENPP2SCN9AJAK2JAK1 | |
| SCHEMBL6003649 | 0.85 | ENPP2 (0.38) | ACKR3ENPP2SCN9AJAK2JAK1 | |
| SCHEMBL4828575 | 0.76 | MAPK14 (0.48) | ACKR3 | |
| SCHEMBL6004463 | 0.72 | ACKR3 (0.36) | ACKR3ENPP2USP30TP53 | |
| SCHEMBL4899267 | 0.71 | USP30 (0.43) | ACKR3USP30 | |
| SCHEMBL4889025 | 0.71 | PIK3CD (0.39) | ACKR3ENPP2USP30 | |
| SCHEMBL6003951 | 0.70 | NR1H2 (0.47) | ENPP2USP30 | |
| SCHEMBL6004212 | 0.70 | ACKR3 (0.38) | ACKR3JAK2JAK3USP30 | |
| SCHEMBL6004214 | 0.70 | TACR1 (0.33) | ACKR3TACR1 | |
| SCHEMBL4832476 | 0.70 | USP30 (0.40) | ACKR3ENPP2JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | ACKR3 262/4885ENPP2 266/4885SCN9A 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.